Skip to main content

Table 4 Changes in mean score for QoL and symptoms

From: Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

QoL items

Baseline mean (standard deviation)

2nd cycle mean (standard deviation)

p value

Global QoL

36.0 (24.7)

55.4 (16.2)

0.01

Physical functioning

47.47 (24.74)

65.22 (20.59)

0.01

Role functioning

42.67 (35.05)

56.52 (25.99)

0.03

Emotional functioning

67.67 (28.39)

84.78 (19.57)

<0.01

Cognitive functioning

66.00 (28.66)

76.09 (18.69)

0.08

Social functioning

42.67 (32.30)

60.87 (26.88)

0.01

Symptoms items

   

   Fatigue

64.89 (25.99)

45.89 (22.30)

<0.01

   Appetite loss

41.33 (36.36)

20.29 (24.08)

0.01

   Dyspnoea

60.44 (28.16)

39.61 (23.88)

<0.01

   Coughing

58.67 (36.36)

28.99 (30.66)

<0.01

   Haemoptysis

12.00 (18.95)

7.25 (17.28)

0.21

   Pain in chest

36.00 (33.22)

17.39 (19.77)

0.04

   Pain in arm or shoulder

24.00 (28.09)

13.04 (19.43)

0.03

   Pain in other parts

25.33 (27.69)

14.49 (22.08)

0.02

  1. QoL, quality of life